The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation-Reference-Cited by-同舟云学术

The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation

Published:2013-12 Issue:S1 Volume:22 Page:63-72
ISSN:1547-3287
Container-title:Stem Cells and Development
language:en
Short-container-title:Stem Cells and Development

Author:

Brindley David A.¹²³⁴,French Anna²⁵⁶,Suh Jane²³⁷,Roberts MacKenna²,Davies Benjamin¹²,Pinedo-Villanueva Rafael¹⁸,Wartolowska Karolina¹,Rooke Kelly¹,Kramm Anneke¹,Judge Andrew¹⁸,Morrey Mark⁹,Chandra Amit¹⁰,Hurley Hannah²,Grover Liam¹¹,Bingham Ian¹²,Siegel Bernard¹³,Rattley Matt S.¹⁴,Buckler R. Lee¹⁵¹⁶,McKeon David¹⁷,Krumholz Katie¹⁷,Hook Lilian¹⁸,May Michael¹⁹,Rikabi Sarah⁵,Pigott Rosie²,Morys Megan²,Sabokbar Afsie¹,Titus Emily¹⁹,Laabi Yacine²⁰,Lemaitre Gilles²⁰,Zahkia Raymond²⁰,Sipp Doug²¹,Horne Robert²⁴,Bravery Christopher²²,Williams David¹⁰,Wall Ivan²³²⁴²⁵,Snyder Evan Y.²⁶²⁷²⁸,Karp Jeffrey M.³²⁹³⁰,Barker Richard W.²,Bure Kim³¹,Carr Andrew J.¹²,Reeve Brock³

Affiliation:

1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom.

2. The Oxford–UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), The University of Oxford, Oxford, United Kingdom.

3. Harvard Stem Cell Institute, Cambridge, Massachusetts.

4. Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, United Kingdom.

5. Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, United Kingdom.

6. Stem Cell Research Laboratory, National Health Service Blood and Transplant, John Radcliffe Hospital, Oxford, United Kingdom.

7. Harvard Department of Stem Cell and Regenerative Biology, Cambridge, Massachusetts.

8. MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Southampton, United Kingdom.

9. Department of Orthopedic Surgery, Mayo Clinic, Minnesota.

10. Centre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, United Kingdom.

11. School of Chemical Engineering, University of Birmingham, Edgbaston, United Kingdom.

12. IP Asset, Oxford, United Kingdom.

13. Genetic Policy Institute, Palm Beach Executive Center, Palm Beach, Florida.

14. Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, United Kingdom.

15. CTG Consulting Co., Inc., Vancouver, Canada.

16. Cell Therapy Group, Bellingham, Washington.

17. The New York Stem Cell Foundation, New York, New York.

18. UK Cell Therapy Catapult Ltd, London, United Kingdom.

19. The Centre for Commercialization of Regenerative Medicine, The Banting Institute, Toronto, Ontario, Canada.

20. I Stem, Evry Cedex, France.

21. RIKEN Center for Developmental Biology, Kobe, Japan.

22. Consulting on Advanced Biologicals Ltd. Units 15 and16, London, United Kingdom.

23. Department of Biochemical Engineering, University College London, London, United Kingdom.

24. Department of Nanobiomedical Science & BK21 Plus NBM Global Reserch Center for Regenerative Medicine, Dankook University, Cheonan 330-714, Republic of Korea.

25. Biomaterials and Tissue Engineering Lab, Department of Nanobiomedical Science and WCU Research Center, Dankook University, Cheonan, South Korea.

26. Sanford-Burnham Medical Research Institute, La Jolla, California.

27. Department of Pediatrics, University of California-San Diego, La Jolla, California.

28. Sanford Consortium for Regenerative Medicine, La Jolla, California.

29. Division of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

30. Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.

31. TAP Biosystems, Hertfordshire, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Cell Biology,Developmental Biology,Hematology

Link

https://www.liebertpub.com/doi/pdf/10.1089/scd.2013.0403

Reference32 articles.

1. Prize-based contests can provide solutions to computational biology problems

2. Commercialization of Regenerative Medicine: Learning from Spin-Outs

3. Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells”

4. Origins and implications of pluripotent stem cell variability and heterogeneity

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell-based therapies for the treatment of sports injuries of the upper limb;Expert Opinion on Biological Therapy;2021-05-31

2. Traceability in stem cell research: from participant sample to induced pluripotent stem cell and back;Regenerative Medicine;2016-01

3. StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium;Stem Cell Reviews and Reports;2015-05-30

4. Application of biomaterials to advance induced pluripotent stem cell research and therapy;The EMBO Journal;2015-03-12

5. CASMI TSCC Launch Event, Paris, France, July 2013: An Assessment of the Key Barriers to the Commercialization and Clinical Adoption of Pluripotent Stem Cell Therapies;Rejuvenation Research;2014-02